A REVIEW Oral Sub Mucous Fibrosis: A Review
Oral Sub Mucous Fibrosis is a well- recognized clinical entity, known since the time of Sushruta. In the modern literature OSMF was first reported by Schwartz (1952), Joshi (1953) was the first person to describe this entity in India. Oral Sub Mucous Fibrosis (OSMF) is a potentially malignant disease that results in progressive juxtaepithelial fibrosis of the oral soft tissues, resulting in increasing loss of tissue mobility, marked rigidity and an eventual inability to open the mouth. The basic change is a fibroelastic transformation of the connective tissue in the lamina propria followed by vesicle formation. It is a well-known chronic insidious disease, precancerous condition, an autoimmune and collagen related disorder whose origin is multifactorial and is associated with chewing of betel quid. It is characterized by progressive hyalinization of the lamina propria. In the later stages the oral mucous membrane becomes very stiff and the patient suffers from trismus and hence difficulty in eating. Earlier OSMF had been confined to countries like India, Pakistan, Bangladesh, etc., but now it is being reported from western countries as well. Inspite of intensive research over the years, a single etiologic factor for OSMF cannot be pointed out with certainty. Patients suffering with OSMF are initially present with a blanched or marble‑like pale mucosa, vesiculations and also show intolerance to hot and spicy food. The treatment of oral submucous fibrosis includes iron, multivitamins including lycopene, spirulina, pentoxifyline, colchicine local submucosal injections of steroids, hyaluronidase and chylomicrons, and surgical excision of the fibrous bands.
Keywords: Oral Sub Mucous Fibrosis, juxtaepithelial fibrosis, oral soft tissues, fibroelastic, lamina propria, collagen.
2. Chole R.H, Patil R , Drug Treatment of Oral Sub Mucous Fibrosis – A Review, International Journal of Contemporary Medical Research, 2016; 3(40.
3. Agrawal A, Kaushal Y, Vaidya S, Shrivastava K, Medical management of oral submucous fibrosis, International Journal of Otorhinolaryngology and Head and Neck Surgery 2017; 3(3):628-631
4. Hebbar PB, Sheshaprasad R, Gurudath S, Pai A, Sujatha D, Oral Sub Mucous Fibrosis in India: Are we progressing?? Indian Journal of Cancer • July 2014
5. Gupta M, Mishra P, Shrivastava K, Singh N, Singh P, A Review Oral Submucous Fibrosis- Current Concepts of Aetiology & its Management , 2015; 1(1).
6. Lai DR, Chen HR, Lin LM, Huang YL , Tsai CC,Clinical evaluation of different treatment methods for oral submucous fibrosis. A 10-yearexperience with 150 cases. Journal of Oral Pathology and Medicine 1995: 24:402-6
7. Anantha N, Nandakumar A, Vishwanath N, Venkatesh T, Pallad YG, Manjunath P, et al. Efficacy of an anti‑tobacco community education program in India. Cancer Causes Control 1995; 6:119‑29.
8. Warnakulasuriya S. Squamous cell carcinoma and precursor lesions: Prevention. Periodontol 2000; 2011:57:38‑50.
9. Kerr AR, Warnakulasuriya S, Mighell AJ, Dietrich T, Nasser M, Rimal J, et al. A systematic review of medical interventions for oral submucous fibrosisand future research opportunities. Oral Dis 2011;17:42‑57
10. Jiang X, Hu J. Drug treatment of oral submucous fibrosis: A review of the literature. J Oral Maxillofac Surg 2009; 67:1510‑5.
11. Chole RH, Gondivkar SM, Gadbail AR, Balsaraf S, Chaudhary S, Dhore SV,et al. Review of drug treatment of oral submucous fibrosis. Oral Oncol 2012; 48:393‑8.
12. Kar IB, Sethi AK. A rare ocular complication following treatment of oral submucous fibrosis with steroids. Natl J Maxillofac Surg 2011; 2:93‑5.
13. Mukherjee S, Ray JG, Chaudhuri K. Zinc and vitamin A as a low cost management of oral submucous fibrosis: Comment on Chole RH et al. “Review of drug treatment of oral submucous fibrosis. Oral Oncol 2012; 48:e27‑8.
14. Kumar A, Bagewadi A, Keluskar V, Singh M. Efficacy of lycopene in the management of oral submucous fibrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 103:207‑13.
15. Kerr AR. Efficacy of oral lycopene in the management of oral submucous fibrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 103:214‑5.
16. Rajendran R, Rani V, Shaikh S. Pentoxifylline therapy: A new adjunct in the treatment of oral submucous fibrosis. Indian J Dent Res 2006; 17:190‑8.
17. Sharma JK, Gupta AK, Mukhija RD, Nigam P. Clinical experience with the use of peripheral vasodilator in oral disorders. Int J Oral Maxillofac Surg 1987; 16:695‑9.
18. Routray S, Motgi AS, Sunkavalli A. Comment on “Chole RH et al. Review of drug treatment of oral submucous fibrosis. Oral Oncol 2012; 48: e13‑4.
19. Sankaranarayanan S, Ramachandran CR, Manjunath S, Murugan P et.al,(June 2008). Autologous Bone Marrow stem cells for treatment of Oral Sub-Mucous Fibrosis - a case report. Sixth Annual Meeting of International Society for Stem Cell Research (ISSCR). Philadelphia.
20. Abraham S, Sankaranarayanan S, Padmanaban J, Baskar S et.al (June 2008). Autologous Bone Marrow Stem Cells in Oral Submucous Fibrosis – Our experience in three cases with six months follow-up. 8th Annual Meeting of Japanese Society of Regenerative Medicine. 68. Tokyo, Japan. pp. 233–55.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).